Rossari Biotech Limited has informed the Exchange about Investor Presentation
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech reported its highest-ever quarterly and full-year numbers for FY26. Q4 FY26 revenue grew 18.2% year-on-year to Rs. 684.9 crore, EBITDA rose 11.2% to Rs. 77.3 crore, and profit after tax jumped 33.7% to Rs. 46 crore. For the full year, revenue climbed 15.2% to Rs. 2,396.4 crore and PAT grew 9.4% to Rs. 149.2 crore. All three segments — Home, Personal Care & Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health & Nutrition (AHN) — posted healthy double-digit growth. However, EBITDA margins slipped 80 basis points for the year to 11.9%, hurt by raw material costs and a lag in passing on price hikes. The Board has recommended a dividend of Rs. 0.50 per share.
Strong topline growth and record quarterly numbers are positives for shareholders, though the slight margin contraction may temper near-term excitement. The capacity expansion at Dahej and new R&D facility signal confidence in future growth, while the rephased capex plan suggests management is being cautious amid uncertain market conditions.